CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
1.010
-0.040 (-3.81%)
Nov 4, 2024, 4:00 PM EST - Market closed
CytomX Therapeutics Employees
As of December 31, 2023, CytomX Therapeutics had 122 total employees, including 120 full-time and 2 part-time employees. The number of employees increased by 4 or 3.39% compared to the previous year.
Employees
122
Change (1Y)
4
Growth (1Y)
3.39%
Revenue / Employee
$980,074
Profits / Employee
$90,869
Market Cap
78.90M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
InterCure | 270 |
Metagenomi | 236 |
Rani Therapeutics Holdings | 140 |
RAPT Therapeutics | 131 |
DBV Technologies | 105 |
ALX Oncology Holdings | 72 |
electroCore | 68 |
IO Biotech | 68 |
CTMX News
- 2 months ago - CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors - GlobeNewsWire
- 3 months ago - CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - GlobeNewsWire
- 5 months ago - CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer - GlobeNewsWire
- 5 months ago - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 months ago - CytomX Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 6 months ago - CytomX stock down 30% despite encouraging cancer study results - Invezz
- 6 months ago - CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire